New Delhi: Sun Pharma and Zydus Pharmaceuticals are recalling products in the US market due to manufacturing issues, according to the US Food and Drug Administration (USFDA). The New Jersey-based Sun ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The United States may find it difficult to impose tariffs on Indian pharmaceutical products as it would likely drive up costs and contribute to inflation, according to Vishal Manchanda, Pharma Analyst ...

Ratna Patra, vice chairman of Square Pharmaceuticals, has announced plans to acquire 15 lakh shares of the company at the prevailing market price within the next 30 days. The announcement was made ...

Sun Pharmaceuticals Industries Ltd is quoting at Rs 1673.25, up 1.08% on the day as on 12:49 IST on the NSE. The stock is up 7.36% in last one year as compared to a 1.54% jump in NIFTY and a 8.67% ...

Square Pharmaceuticals' Vice-Chairman Ratna Patra has announced plans to acquire 1.5 million shares of the company. This purchase is valued at approximately Tk33 crore at current market rates. Ratna, ...

On Tuesday, India’s top specialty generics company Sun Pharma announced the acquisition of the US-based Checkpoint for $355 million to enhance its oncology portfolio. Analysts view this ...

Sun Pharma shares rose like the sun in the intraday trade on Tuesday, as the company shares surged by over 2 per cent in the first half of the day's trade. This came to pass after a landmark ...

Samuel S Chowdhury, chairman of Square Pharmaceuticals, yesterday expressed his willingness to purchase 15 lakh shares of the company, valued at over Tk 32 crore at the current market price.

Sun Pharmaceutical Industries Ltd led the gainers, rising 2.62 per cent to close at ₹1,653.30. ICICI Bank followed, advancing 2.49 per cent to ₹1,244.80, supported by strong institutional buying.

Sun Pharmaceutical Industries Ltd has entered into an agreement to acquire US-based immunotherapy and targeted oncology company, Checkpoint Therapeutics Inc, a development that would bring the ...